drugset / Trial / NCT04005339
NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a study to evaluate the clinical activity of the combination of fluorouracil, leucovorin, and nanoliposomal irinotecan as second-line treatment in patients with advanced biliary tract cancers following gemcitabine and platinum chemotherapy.
Timeline
- Start
- 2019-07-29
- Primary completion
- 2025-09-03
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leucovorin | Small molecule | 400 mg | Intravenous |
| Subject | Nanoliposomal Irinotecan | Unknown | 70 mg | Intravenous |
| Subject | fluorouracil | Small molecule | 2400 unknown | Intravenous |